Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Rises By 48.1%

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 479,700 shares, an increase of 48.1% from the August 31st total of 324,000 shares. Based on an average daily volume of 148,500 shares, the short-interest ratio is presently 3.2 days. Currently, 2.9% of the shares of the company are short sold.

Immix Biopharma Price Performance

Immix Biopharma stock traded down $0.03 during midday trading on Friday, hitting $1.56. The company’s stock had a trading volume of 49,845 shares, compared to its average volume of 187,156. The company has a 50-day moving average price of $2.00 and a two-hundred day moving average price of $2.25. Immix Biopharma has a 1-year low of $1.52 and a 1-year high of $7.75. The company has a market cap of $41.21 million, a price-to-earnings ratio of -1.71 and a beta of 0.17.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. Sell-side analysts forecast that Immix Biopharma will post -0.64 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Immix Biopharma in a research report on Monday, August 19th.

Hedge Funds Weigh In On Immix Biopharma

Hedge funds have recently bought and sold shares of the company. Invst LLC acquired a new stake in shares of Immix Biopharma during the 2nd quarter worth approximately $57,000. Tritonpoint Wealth LLC acquired a new stake in Immix Biopharma in the first quarter valued at approximately $75,000. Jump Financial LLC acquired a new position in shares of Immix Biopharma during the fourth quarter worth $128,000. Finally, Tocqueville Asset Management L.P. lifted its stake in shares of Immix Biopharma by 89.0% in the 1st quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock valued at $116,000 after acquiring an additional 17,800 shares during the last quarter. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.